eGenesis
Gene-edited pigs for xenotransplantation and organ transplants
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2015
- Latest Form D
- $25.4M, Feb 2024
- Total capital
- $265M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $265M
- 5 Form D · last Feb 2024
- 32 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 10 pending · first 2024
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$25.4M
- Private capital raisedForm D · SEC · 4th filing$125M
- Private capital raisedForm D · SEC · 3rd filing$100M
- Private capital raisedForm D · SEC · 2nd filing$12.6M
- Private capital raisedForm D · SEC · 1st filing$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing in Biotech · 4373 companies
Line = median- Federal contracts#534 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Luhan YangResearcherExecutive Officer, DirectorLinked by 1 patent
- Albert L. WiegmanDirectorNamed in SEC Form D filings
- Ariel JasieExecutive OfficerNamed in SEC Form D filings
- Bob MoreDirectorNamed in SEC Form D filings
- Boris NikolicDirectorNamed in SEC Form D filings
- Brad SmithDirectorNamed in SEC Form D filings
Show all 24 people
- Geoff MacKayExecutive OfficerNamed in SEC Form D filings
- George M. ChurchDirectorNamed in SEC Form D filings
- Isaac CiechanoverDirectorNamed in SEC Form D filings
- Jennifer BergheiserExecutive OfficerNamed in SEC Form D filings
- Juergen L. EckhardtDirectorNamed in SEC Form D filings
- Julie SunderlandDirectorNamed in SEC Form D filings
- Kathleen FanningDirectorNamed in SEC Form D filings
- Kenneth FanExecutive OfficerNamed in SEC Form D filings
- Lucio IannoneDirectorNamed in SEC Form D filings
- Mark PruzanskiDirectorNamed in SEC Form D filings
- Michael CurtisExecutive OfficerNamed in SEC Form D filings
- Paul SekhriExecutive Officer, DirectorNamed in SEC Form D filings
- Peter HansonExecutive OfficerNamed in SEC Form D filings
- Rahul KakkarDirectorNamed in SEC Form D filings
- Sapna SrivastavaExecutive OfficerNamed in SEC Form D filings
- Sarah SchlesingerDirectorNamed in SEC Form D filings
- Stephen GillisDirectorNamed in SEC Form D filings
- Steven GillisDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 13- GrantedCells, Tissues, Organs, And Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And ToleranceUSPTOUS 12,637,690
- GrantedCells, Tissues, Organs, And Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And ToleranceUSPTOUS 12,630,838
- PendingCells, Tissues, Organs, And Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And ToleranceUSPTOApplication 19414047
Show all 13 patent records
- Cells, Tissues, Organs, And Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And ToleranceMay 26, 2026 · US 12,637,690Granted
- Cells, Tissues, Organs, And Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And ToleranceMay 19, 2026 · US 12,630,838Granted
- Cells, Tissues, Organs, And Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And ToleranceApr 9, 2026 · Application 19414047Pending
- Methods For Generating Genetically Modified AnimalsFeb 6, 2025 · Application 18747211Pending
- Method For Generating A Genetically Modified Pig With Inactivated Porcine Endogenous Retrovirus (perv) ElementsAug 13, 2024 · US 12,058,986Granted
- Methods For Generating Genetically Modified AnimalsApplication PCTUS2018028539Pending
- Methods For Generating Genetically Modified AnimalsApplication 62543610Pending
- Perv-free Porcine Cells And Methods Of UseApplication 62527702Pending
- Perv-free Porcine Cells And Methods Of UseApplication 62487898Pending
- Cells, Tissues, Organs, And Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And ToleranceApplication PCTUS2021059265Pending
- Cells, Tissues, Organs, And/or Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And/or ToleranceApplication 63247544Pending
- Cells, Tissues, Organs, And/or Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And/or ToleranceApplication 63218080Pending
- Cells, Tissues, Organs, And/or Animals Having One Or More Modified Genes For Enhanced Xenograft Survival And/or ToleranceApplication 63113650Pending
Related companies, and why
- Rakuten Medical, Inc.Similar federal contract value in Biotech · null in contracts
- SeaStar Medical Holding CorpSimilar federal contract value in Biotech · null in contracts
- EvommuneSimilar federal contract value in Biotech · null in contracts
- Verona Pharma plcSimilar federal contract value in Biotech · null in contracts
- Capstan TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Apnimed, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .